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A workflow for the orthogonal identification of 
biotransformation products by HILIC-QTOFMS
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 Determine the degradation rate of emerging contaminants
(pharmaceuticals, illicit drugs) in the aquatic environment under aerobic
conditions
 Study the occurrence and formation of transformation products
 Develop an integrated workflow for suspect and non-target
screening for the identification of biotransformation products
 Study the use of HILIC as a complementary technique for the
identified TPs
 Further investigation for suspect and unknown TPs which may be
eluted better in HILIC conditions
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3Samples of activated sludge from active bioreactors and effluent 
waste water from the WWTP of Athens (Psitalia)
Batch reactors seeded with activated sludge under aerobic  
conditions in room temperature
Spike in a concentration of 2 mg/L
Sampling immediately after spiking and after several time 
intervals (depending on the compound)
Filtration through glass fiber syringe and then through 0.2 μm RC 
filter
LC-HRMS (qTOF) both RP and HILIC
Check for 







Prior to the 

















All reactors were 
covered with 
perforated caps and 
placed on a 
magnetic stirrer to 
aerate the sludge.
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Column: Thermo Acclaim RSLC 
C18, 2.2μm 120 Å, 2.1x100 mm
Mobile Phase & gradient 
program: Bruker Pesticide 
screener
Inj. Volume: 5 μL
Column: Waters BEH Amide 
Acquity 1.7 μm, 2.1×100 mm 
Inj. Volume: 5 μL
Bruker Maxis Impact™ 
Quadrupole-Time-of-Flight
UltiMate 3000™ 




Schymanski et al. Environmental Science and Technology (2014) 48(4):2097
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Compilation of suspect list: Metabolite prediction 
tools+ literature
Screening all the time interval chromatograms both in 
RP and HILIC  (+ESI/-ESI)          XIC
Evaluation of candidates (Tentative): meet the set
criteria, absence in the blank, chromatographic
retention time plausibility (time trend)
Acquire MS/MS spectra with inclusion list both in RP 
and HILIC: Interpretation of the fragmentation pathway
Confirmation, if it’s possible with reference standard 
(RT and MS/MS spectra)
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Compilation of the suspect list
•All rules (Phase I & II,
cytochrome P450)
•2 Generations




















Compile the suspect list
Save as  .csv file
•Run Bruker Compass Target Analysis 1.3
•Set appropriate thresholds (m/z tolerance and
mSigma)
•Consider mass accuracy and isotopic pattern
to identify plausible TPs
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Screening all the time interval chromatograms both in RP 




• Mass Accuracy: Error ≤ 
5 ppm
• Distinctive Isotopic fit: ≤ 
100 mSigma






Evaluation of candidates (Tentative): meet the set criteria,

















Time Profile of CTR TPs in HILIC
CTR 311 CTR 329 CTR 330 CTR 339A CTR 339B
CTR 341 CTR 343 CTR 344 CTR 355 CTR 357















Time Profile f CTR minor TPs in HILIC
CTR 329 CTR 330 CTR 339B CTR 355 CTR 357
CTR 359A CTR 359B CTR 360A CTR 360B
Until now, Identification level 5: Exact mass of Interest
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Acquire MS/MS spectra with inclusion list both in RP and 
HILIC: Interpretation of the fragmentation pathway CTR 343
Data 
analysis
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RAN Biotic t24h_GA7_01_6740.d: EIC 301.1329±0.005 +All MS


















































































Carboxylic acid of 
CTR N-oxide
Hydroxylated derivative 































50 100 150 200 250 300 350 m/z
342.1500 -H2O
-H2O
































elimination of  H2O: 
characteristic 
fragmentation pattern 







only in CTR N-oxide











































































Identification level 1: Confirmation with Reference 
Standard
Subtraction of the background (Bruker’s MetaboliteDetect 2.0)
Generation of a peak list of unknown











eXpose mode, Ratio: 3
Detect -Mass spectrum 
Parameters
Int. threshold: 30%













































LDC207 207.1504 C12H18N2O 7d ↗↘ 1 MEGX
LDC251 251.1756 C14H22N2O2 2d ↗↘ 1 Lidocaine-N-oxide
LDC219 219.1485 C13H18N2O 1d ↗↘ 2b
LDC233 233.1282 C13H16N2O2 7d ↗→ 4








CTR311 311.1554 C19H19FN2O 6 d ↗ 1 Desmethyl CTR
CTR329 329.1660 C19H21FN2O2 6 d ↗ 2b Desmethyl CTR amide
CTR330 330.1500 C19H20FNO3 6 d ↗ 2b Desmethyl CTR carboxylic acid
CTR339A 339.1503 C20H19FN2O2 6 d ↗ 1 3-Oxo-CTR
CTR339B 339.1880 C21H23FN2O 6 d ↗ 2b Methylated derivative of CTR
CTR341 341.1660 C20H21FN2O2 3 d ↗↘ 2a CTR-N-oxide
CTR343 343.1816 C20H23FN2O2 6 d ↗ 1 CTR amide
CTR344 344.1656 C20H22FNO3 5 d ↗ 1 CTR carboxylic acid
CTR355 355.1457 C20H19FN2O3 6 d ↗ 3 Hydroxylated derivative of 3-Oxo-CTR
CTR357 357.1609 C20H21FN2O3 6 d ↗ 2b Amide of 3-Oxo-CTR
CTR359A
359.1765 C20H23FN2O3
6 d ↗ 3 Hydroxylated derivative of CTR amide
CTR359B 4 d ↗↘ 2b Amide of CTR-N-oxide
CTR360A
360.1606 C20H22FNO4 6 d
↗ 3 Hydroxylated derivative of  CTR carb.acid
CTR360B ↗ 2b Carboxylic acid of CTR-N-oxide
M
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1d ↗↘ 4 -
RAN286B
2d ↗→ 4 -
RAN286C
10h ↗↘ 4 -
RAN301A











RAN316B 3d ↗ 3
RAN317 
(2peaks)
317.1278 C12H20N4O4S 3d ↗ 3 Desmethyl RAN-S-oxide
RAN331A 
(2peaks) 331.1435 C13H22N4O4S
1d ↗↘ 1 RAN-S-oxide








n ATR515 515.2341 C31H31FN2O4 2d ↗ 2b β-oxidation product of ATR





ATR487B 2d ↗ 3
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5 pharmaceuticals (metformin, ranitidine, lidocaine, citalopram and
atorvastatine) were investigated for their TPs under aerobic
biodegradation experiments and 34 TPs were identified, in total.
Nine of them were confirmed by a reference standard and the
majority of the rest reached Id. Level 2: probable structure by
diagnostic evidence.
HILIC was presented to be fit for the orthogonal identification of TPs
and suitable for screening of more polar metabolites
HILIC provided better peak shapes and greater intensities in some of
the identified TPs.
HILIC also, permitted the identification and characterisation of
isomeric TPs, due to the better detection sensitivity that provided
clearer spectra for interpretation.
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